entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 12:30:34 - browse：176

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： House GOP plan to stem drug shortages differs from Democrats’

focus

hotspot

WSS

Teacher posts viral 'school supply rant' with advice for parents

Readout Newsletter: Beam, Prozac, "TechBio" and more

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Medicare Advantage isn’t working — for anyone

Virtual repurposing can help discover new uses for existing drugs

Using force crossed my mind when examining a defiant young patient

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

In Memoriam: Notable people who died in 2023

5 wounded, 2 critically, in Michigan shopping center shooting

Anesthesiologist group: stop taking Ozempic before surgery

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

23andMe had bad news about my health. I wish a person had delivered it

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

focus

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

5 ways to address the shortage of health care workers

Teacher posts viral 'school supply rant' with advice for parents

Virtual repurposing can help discover new uses for existing drugs

Are embryos people? Reproductive medicine's future depends on the answer

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

focus

hotspot

entertainment

focus